PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone
In This Article:
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.